Articles On Dimerix (ASX:DXB)
Title | Source | Codes | Date |
---|---|---|---|
Guess which ASX healthcare share is rocketing 130% on some big news
The Dimerix Ltd (ASX: DXB) share price has returned from its trading halt with a bang on Thursday. In morning trade, the ASX healthcare share was up a massive 130% to 14 cents. It has since pulled back but remains up an impressive 89% to 1... |
Motley Fool | DXB | 6 months ago |
Dimerix and Advanz Pharma enter agreement to commercialise DMX-200 in major markets
Advanz Pharma and Dimerix (ASX:DXB) have announced they have entered into an exclusive license agreement for the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand for the commercialisation of Dimerix’s... |
BiotechDispatch | DXB | 6 months ago |
Closing Bell: Noxopharm ignores screams as unsuspecting local markets ambushed by hellish bank-tech-comms beastie
Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-... |
Stockhead | DXB | 6 months ago |
ASX Today: Stocks to watch on Wednesday
ASX futures were down 0.51 per cent approaching 9:30 am AEDT after all major US bourses ended in the red overnight. It looks like the passing of September, notorious for being the worst month on the ASX at least, hasn’t hit the USA’s in... |
themarketherald.com.au | DXB | 6 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | DXB | 6 months ago |
US FDA grants conditional approval to the brand name of Dimerix's DMX-200
Dimerix (ASX:DXB) has announced that the US FDA has given conditional approval for the brand name QYTOVRA for its Phase 3 clinical drug candidate. |
BiotechDispatch | DXB | 6 months ago |
FDA approves commercial brand name for Dimerix’s kidney disease drug
FDA grants conditional approval for commercial brand name QYTOVRA Treatment targets billion-dollar market opportunity in rare FSGS kidney disease Treatment already has orphan drug designation Phase 3 clinical trial is progressing The US... |
Stockhead | DXB | 7 months ago |
ASX Health Stocks: Starpharma full steam ahead on VIRALEZE study, Dimerix to use QYTOVRA as brand name
Dimerix’s drug granted QYTOVRA as brand name by US FDA Starpharma completes recruitment for VIRALEZE study in UK Invion adds South Korea to list of exclusive territories for Photosoft FDA says QYTOVRA can be used as DMX-200 brand name... |
Stockhead | DXB | 7 months ago |
2023 ASX biotech darling Neuren among sector stocks with upcoming catalysts
2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t... |
Stockhead | DXB | 7 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | DXB | 7 months ago |
In Case You Missed It: A consumer products divestment and a dash of lithium
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today. ICYMI Leader... |
Stockhead | DXB | 7 months ago |
ASX Today: Stocks to watch on Wednesday
Futures have predicted the ASX will open slightly lower today, driven by a mixed afternoon of trading on Wall Street and the underperformance of tech stocks. On home soil, today marks the eagerly awaited High Court decision that will det... |
themarketherald.com.au | DXB | 7 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | DXB | 7 months ago |
Introducing: Our Biotech Pick of the Year 2021
Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021. |
nextinvestors.com.au | DXB | 7 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | DXB | 7 months ago |
Move over Neuren – Bioshares reckons these ASX health stocks could pop with upcoming key catalysts
Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing... |
Stockhead | DXB | 8 months ago |
In Case You Missed It: Canadian lithium and nickel next door to Chalice
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 8 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | DXB | 8 months ago |
MoneyTalks: Why Peak Asset Management is betting on these biotech and lithium plays
MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Peak Asset M... |
Stockhead | DXB | 8 months ago |
In Case You Missed It: A new lithium player launches and high-grade REE in the NT
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 8 months ago |
In Case You Missed It: Coal is king today but clean lithium ain’t far behind
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 8 months ago |
In Case You Missed It: Iron ore and diabetic pet test distribution deals
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 8 months ago |
Dimerix achieves successful second key review for its Phase 3 FSGS kidney disease trial
Dimerix has achieved another key milestone in its ACTION 3 Focal Segmental Glomerulosclerosis (FSGS) trial with the Data Safety Monitoring Board (DSMB) safety review giving it the green light to continue as planned. Dimerix (ASX:DXB) has... |
Stockhead | DXB | 8 months ago |
Dimerix announces successful completion of second DSMB review of ACTION3 trial
Dimerix (ASX:DXB) has announced that the independent Data Safety Monitoring Board has successfully concluded a second review of the ACTION3 phase 3 clinical trial. |
BiotechDispatch | DXB | 8 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | DXB | 8 months ago |
In Case You Missed It: Breast cancer test success and new scanner tech launched in US lottery tickets
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 8 months ago |
In Case You Missed It: Imminent copper production, and comms company could meet full year guidance
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 8 months ago |
Dimerix updates on expected timing of DMX-200 Phase 3 kidney trial outcome
Dimerix (ASX:DXB) has confirmed that the first 72 patients have been randomised in its DMX-200 ACTION3 phase 3 trial in patients with FSGS kidney disease. |
BiotechDispatch | DXB | 9 months ago |
In Case You Missed It: It’s all gold
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 9 months ago |
With patient randomisation complete, Dimerix locks in Q1 2024 window for part 1 of its Phase 3 FSGS kidney disease trial outcome
Dimerix has achieved a key milestone in its global Phase 3 Focal Segmental Glomerulosclerosis (FSGS) trial with the last patient of the first 72 patient cohort now randomised, locking in a March 2024 date for interim outcome results. Dim... |
Stockhead | DXB | 9 months ago |
ASX Today: Stocks to watch on Monday
Futures suggest the ASX will open higher before the release of Australia’s inflation figures and the interest rate decisions from the Federal Reserve and ECB. Meanwhile, the Aussie dollar is down 0.7 per cent to 67.29 US cents. Here... |
themarketherald.com.au | DXB | 9 months ago |
In Case You Missed It: Lithium, Nootropics and a dash of nickel
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 9 months ago |
Peak Asset Management brings the Microcap Mountain to the people in Melbourne.
Peak Asset Management recently held its first Microcaps investor conference, and here’s what the punters and players had to say about it. In mid July, boutique firm Peak Asset Management organised its inaugural microcap investor conference,... |
Stockhead | DXB | 9 months ago |
In Case You Missed It: Gold, drones and another Canadian lithium play
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 9 months ago |
In Case You Missed It: Nickel, copper and gold make a splash
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 9 months ago |
In Case You Missed It: Medicare delays and lithium giant invests in WA player
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 9 months ago |
Dimerix receives European approval for paediatric investigation plan
Dimerix (ASX:DXB) has announced that the Paediatric Committee of the European Medicines Agency has accepted its Paediatric Investigation Plan for the development of DMX-200 for focal segmental glomerulosclerosis following the PDCO m... |
BiotechDispatch | DXB | 9 months ago |
Come and meet some small caps rockstars at the upcoming Peak Asset Management Microcap Conference in Melbourne
Peak Asset Management, with the support of Stockhead, is giving you the chance to go 1-on-1 with some of the leading ASX small caps CEOs and property gurus from a range of market sectors in Melbourne, on 13 July, 2023. The hectic landscape... |
Stockhead | DXB | 9 months ago |
Dimerix receives approval for paediatric investigation plan in Europe
In a major milestone, Dimerix has received endorsement by the European Medicines Agency (EMA) to include children in Europe in its pivotal ACTION3 trial. Dimerix (ASX:DXB) has announced that the Paediatric Committee (PDCO) of the EMA has... |
Stockhead | DXB | 9 months ago |
ASX Today: Stocks to watch on Monday
Futures suggest the ASX will climb as the new financial year takes off, bolstered by hopes that the RBA will hit pause ahead of its next rates decision tomorrow. Here are some ASX-listed companies with news out today: Larvotto Resourc... |
themarketherald.com.au | DXB | 9 months ago |
In Case You Missed It: Gold hits, zinc-lead-copper and lithium ground snapped up
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 9 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | DXB | 10 months ago |
In Case You Missed It: Gold mining, a media acquisition and some lithium
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 10 months ago |
In Case You Missed It: Gold, rare earths and a digital healthcare deal
Stockhead’s In-Case-You-Missed-It highlights some strongest-performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 10 months ago |
In Case You Missed It: Nickel hits, Canadian lithium and some more nickel
Stockhead’s In-Case-You-Missed-It highlights some strongest-performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | DXB | 10 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | DXB | 10 months ago |
Dr Boreham’s Crucible: Dimerix
By Tim Boreham ASX code: ((DXB)) Share price: 7.0c Shares on issue: 320,748,666* Market cap: $22.5m Chief executive officer: Dr Nina Webster Board: Hugh Alsop (chair), Dr Webster, Dr Sonia Poli, Clinton Snow Financials (March quarter 2023):... |
FNArena | DXB | 10 months ago |
Dimerix raises $8.7 million to advance Phase 3 trial for kidney drug
In a tough market environment Dimerix has announced it has raised close to $9 million as it moves to advance its Phase 3 Focal Segmental Glomerulosclerosis (FSGS) clinical trial past first interim data. Clinical stage biopharmaceutical comp... |
Stockhead | DXB | 10 months ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | DXB | 10 months ago |
In Case You Missed It: Cannabis play leads by miles
Stockhead’s In-Case-You-Missed-It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag... |
Stockhead | DXB | 10 months ago |